Viral inhibitor composition for in vivo therapeutic use
AssigneeCesa Alliance S.A.
InventorChristine Coppens
Life of this patent
Estimating the term…
Abstract
The present invention concerns a pharmaceutical composition comprising a compound of formula A being (2,3(dihydroxy), 5[3(1,2)butadiene], 1(3hydroxy,3methyl,4pentene)benzene) and/or a compound of formula B being (2,3(dihydroxy), 5[3(1,2)butadiene], 2[2methylbutane]benzenal) and/or a compound of formula C being (2,3(dihydroxy), 5[3(1,2)butadiene], 2hydroxy,3butene benzoate) or a combination thereof for use as a medicament or for in vivo use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.
Claims18
A compound having a structure according to any one of Formula A, Formula B, or Formula C
A pharmaceutical composition comprising:
- a carrier;
- and
- a compound having a structure according to Formula A, Formula B, or Formula C,
- wherein the compound is present in an amount effective to reduce a viral load of at least one of herpes labialis, human papillomavirus, parvovirus, Porcine Reproductive and Respiratory Syndrome (PRRS) virus, and rotavirus in a mammal when administered to the mammal.
A method of treating a mammal for at least one of herpes labialis, papillomavirus, parvovirus, PRRS, and rotavirus comprising:
- providing a pharmaceutical composition comprising a compound having a structure according to Formula A, Formula B, or Formula C,
- wherein the compound is present in the pharmaceutical composition in an amount effective to treat the at least one of herpes labialis, papillomavirus, parvovirus, Porcine Reproductive and Respiratory Syndrome (PRRS) virus, and rotavirus when administered to a human in need thereof;
- and
- administering the pharmaceutical composition to the human under a protocol effective to treat the at least one of herpes labialis, papillomavirus, parvovirus, PRRS, and rotavirus.
A method of reducing the incidence of infection of a human with at least one of herpes labialis, human papillomavirus, parvovirus, Porcine Reproductive and Respiratory Syndrome (PRRS) virus, and rotavirus comprising:
- providing a pharmaceutical composition comprising a compound having a structure according to Formula A, Formula B, or Formula C,
- wherein the compound is present in an amount effective to reduce the likelihood that the at least one of herpes labialis, human papillomavirus, parvovirus, Porcine Reproductive and Respiratory Syndrome (PRRS) virus, and rotavirus will infect the human;
- and
- administering the pharmaceutical composition to the human using a protocol effective to reduce the likelihood that the at least one of herpes labialis, human papillomavirus, parvovirus, Porcine Reproductive and Respiratory Syndrome (PRRS) virus, and rotavirus will infect the human.
A method of disinfecting a non-human surface comprising:
- providing a disinfectant composition comprising at least one of Formula A, Formula B, and Formula C;
- applying the disinfectant composition under a protocol effective to deactivate the at least one of herpes labialis, human papillomavirus, parvovirus, Porcine Reproductive and Respiratory Syndrome (PRRS) virus, and rotavirus.
Dependencies are inferred from the claim text.